joining today's Thank on you, call. and afternoon, us conference thanks for Good everyone, Patrick.
quarter clinical NAV will We'll a call programs of as an update recent expected the Technology of Steve, our milestones. We of for financial progress provide will results the update provide then advancing expanding an will provide the full future our Platform the questions. on and and year fourth as open Vit and recap well for XXXX.
therapy So of the advancing based gene decade, can and proprietary We significantly of mission therapy to pipeline we REGENXBIO's on the potential NAV through disease curative patient monogenic improve across clear replacement. and treatments believe two are AAV-mediated alter our many course the lives AAV-mediated modalities, course gene technology broadening over the treatment our has administration of delivery populations single and gene past platform. remained antibody in
Technology from NAV treatments Platform for genetic develop to those diseases and our utilize affecting expanded for modalities health. suffering options diseases potential public Both, potentially broadly both treatment rare
In macular of trial. our strides treatment RGX-XXX. one-time RGX-XXX advancing I/II broadening to Phase degeneration as the XXXX, and continues program well burden, announced improved we following months wet programs. of updated six data demonstrate great a our administration reductions The from anti-VEGF meaningful cohort acuity of as in visual we five lead data pipeline internal month, for gene Last data key our for is which age-related made therapy
steps RGX-XXX look reporting data Further remain in the the by program. from data to next and and longer regarding We the results, this strongly durability encouraged in trial XXXX. Phase the plan we clinical efficacy program's I/IIa term help all cohorts from of us for forward will
central MPS of I/II nervous replacement despite the II significant Phase availability continue in provide in recent II data first trial our address with Beyond system. difficulties interim RGX-XXX, we're three to neurocognitive patients enzyme RGX-XXX. disease MPS Patients for which the from doesn't manifestations therapy the have excited of to the
magna RGX-XXX one-time to a relatively through using was cohort approach new the from administration of data showed cisterna initial delivery therapy first that gene the following well-tolerated direct-to-CNS The approach.
reduction patients Phase sustained patients and for This trial the in and half neurocognitive our we data in well the importantly, steroid an treatment after X of assess dosing stability. in completed biomarker of this prophylaxis completed a of Cohort signs consistent homozygous of as I/II familial We’ve expanded key hypercholesterolemia Equally of available RGX-XXX have also interim as or plan should we be HoFH treatment. the levels LDLC and first year. to observed
which Across key on antibodies unregulated on kallikrein, is REGENXBIO, for protein patients with preclinical HAE. in contact important the work plasma of research angioedema treatment R&D the team and a at based is continuing directed potential plasma hereditary pathway, left
expansion exclusive Neurimmune, alpha-synuclein collaboration with targeting vectorized and design therapies also We tau. the recently announced antibody and to and develop
on update provide half XXXX. second an of the We expect these programs in to
Elsewhere, Olivier myopathy. targeting Vector muscle the Officer, by of AAVX treatments NAV led recognized cells, the our in partners also has utility as Science team like myotubular R&D our work Danos, some in for Technology evidenced X-linked treatment by the specifically our our Audentes of of Chief
we’ve As result, of a indications. our pipeline had focused in number ongoing neuromuscular research on a work
to starting diseases currently selection, is approaching candidate the treat neuromuscular therapies. now is a believe who have stage of work potential we and we treatment currently the options or suffering existing opportunity this and by certain of from mature lack to Some patients underserved
providing these forward we as of continue half that’s deep we’ve a AAV to production and work of understanding scale AAV further develop in-house on the potential to knowledge strong indications. that to of of developed application biology, this for treatments in neuromuscular in models types the the I disease updates the of and manufacturing it necessary of feel specific We evidence second a year. AAV look the
production patients. construction here the strategically Maryland Rockville, is Related, quality site our planned. scale provide as to for us in facility production to ensuring The of continues while CGMP ability expected
to those supply operational and may be of including are be we on and XXXX. late-stage supporting early require programs expect track which large-scale to in capable vector We
I’d a especially to Before turning patient like Steve, the to communities. over it to our express gratitude, physician moment take and to
big our week that in raise round, and Rare a we are is related for diseases. efforts do worldwide February the of with that is Day is we and activities to work for and month, awareness disease associated to devastating rare appreciation participating While this patients rare work Disease year
physicians we from heard patient disease yesterday, in work. that at groups our event patients Just of where an rare we and of who had with those recognition all-staff including center diseases the are treat month, rare
continue remain to curative working the committed promise to rare NAV in to disease treatments. find of believe the Technology unmet continuing for and and community with We address needs
clinical I'd to over turn like that, With the for to Steve call regulatory update. and
